US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

21.94

+0.54002.52%

Volume:348.46K

Turnover:7.58M

Market Cap:3.86B

PE:-17.58

High:22.22

Open:21.44

Low:21.43

Close:21.40

Loading ...

Overview Company News Filings

Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Thousands of Hyundai iLoad, iMax people movers recalled over fears manufacturing fault could spark fire

Sydney Morning Herald

Hyundai recalls 4700 cars over potentially dangerous fuel defect

Sydney Morning Herald

FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

OneStream Is Maintained at Neutral by Citigroup

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

OneStream Raised to Overweight From Equal-Weight by Morgan Stanley

Morgan Stanley Upgrades Onestream to Overweight From Equalweight, Keeps $37 Price Target

MT Newswires Live

Onestream, Inc. Class A Upgraded to Overweight on Strong Growth Prospects and Attractive Valuation

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Press Release: Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

OneStream Announces Timing of its Fourth Quarter and Full-Year 2024 Financial Results Conference Call

China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer

The Automotive Playground at CES 2025: AI, EVs, Flying Cars & More

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":21.94,"timestamp":1746117560122,"preClose":21.4,"halted":0,"volume":348463,"delay":0,"floatShares":70199725,"shares":176023203,"eps":-1.247698,"marketStatus":"Trading","change":0.54,"latestTime":"05-01 12:39:22 EDT","open":21.44,"high":22.22,"low":21.43,"amount":7580100.306628,"amplitude":0.036916,"askPrice":21.96,"askSize":200,"bidPrice":21.92,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-1.247698,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":21.4,"preHourTrading":{"tag":"盘前","latestPrice":21.68,"preClose":21.4,"latestTime":"09:29 EDT","volume":3962,"amount":85892.85173000001,"timestamp":1746106199999},"postHourTrading":{"tag":"盘后","latestPrice":21.4,"preClose":21.4,"latestTime":"16:12 EDT","volume":22219,"amount":475472.48,"timestamp":1746043930471},"volumeRatio":0.97356,"impliedVol":0.8913,"impliedVolPercentile":0.9579},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":70199725,"roa":"-33.71%","roe":"-102.65%","lyrEps":-1.232998,"volumeRatio":0.97356,"shares":176023203,"dividePrice":0,"high":22.22,"amplitude":0.036916,"preClose":21.4,"low":21.43,"week52Low":16.6942,"pbRate":"10.00","psRate":"7.89","week52High":35.39,"institutionHeld":0,"latestPrice":21.94,"committee":-0.960784,"eps":-1.247698,"divideRate":0,"volume":348463,"delay":0,"ttmEps":-1.247698,"open":21.44,"prevYearClose":28.52,"prevWeekClose":21.29,"prevMonthClose":21.4,"prevQuarterClose":21.34,"fiveDayClose":21.27,"twentyDayClose":22.48,"sixtyDayClose":29.76,"earningDate":1746633600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2506063589","title":"Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2506063589","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506063589?lang=en_us&edition=fundamental","pubTime":"2025-01-28 03:23","pubTimestamp":1738005795,"startTime":"0","endTime":"0","summary":"On Saturday, Pfizer Inc. revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi in combination with cetuximab  and mFOLFOX6  in patients with metastatic colorectal cancer  with aBRAF V600E mutation.At the time of this analysis, the Braftovi combination regimen demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate  compared to patients receiving chemotherapy with or without bevacizumab .Also Read: Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges. The results were presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancer Symposium  and were simultaneously published inNature Medicine.The estimated median duration of response was 13.9 months with Braftovi plus cetuximab and mFOLFOX6 and 11.1 months with chemotherapy with or without bevacizumab.Of patients on Braftovi plus cetuximab and mFOLFOX6, 22.4%  had a response lasting 12 months or longer, compared to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizers-conditionally-approved-braftovi-combo-192315424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1057294990.SGD","SG9999003800.SGD","LU1066053197.SGD","PFE","LU1023059063.AUD","SG9999002232.USD","BK4568","IE00B19Z3B42.SGD","LU0234572021.USD","BK4581","BK4097","LU0321505868.SGD","LU1066051498.USD","BK4585","LU0868494617.USD","PFS","LU1883839398.USD","IE00BLSP4239.USD","BK4599","LU0122379950.USD","LU0225284248.USD","SG9999001176.USD","SG9999011175.SGD","IE00BLSP4452.SGD","BK4534","OS","SGXZ57979304.SGD","ORR","SG9999002224.SGD","BK4211","LU0306807586.USD","LU0289739699.SGD","LU0306806265.USD","LU0985481810.HKD","LU0456855351.SGD","IE000M9KFDE8.USD","LU0225771236.USD","IE00B19Z3581.USD","IE0002270589.USD","IE00BBT3K403.USD","LU1894683264.USD","BK4007","LU1894683348.USD","LU0058720904.USD","BK4550","SG9999013999.USD","BK4592","LU0170899867.USD","SG9999001176.SGD","BK4195"],"gpt_icon":1},{"id":"2506744377","title":"Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2506744377","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506744377?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:00","pubTimestamp":1737986400,"startTime":"0","endTime":"0","summary":"- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT -. - Ad-hoc analyses of pancreatic cancer population subgroups suggest meaningful improvement in median overall survival  for patients treated with Alpha DaRT after prior therapy, compared to previously published studies of alternative monotherapies, across all analyzed subgroups –。- Approval received from France’s Ministry of Health to commence French multicenter clinical trial of Alpha DaRT alongside capecitabine for patients with locally advanced pancreatic cancer -. Across three ongoing feasibility and safety trials, two in Canada and one in Israel, 41 patients with pancreatic cancer had been treated with Alpha DaRT in Canada  and Israel , including the first five patients for whom interim data was already released in late 2023. A 100% success rate was achieved in delivering the Alpha DaRT sources , and strong safety results were o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-tau-announces-cornerstone-interim-140000086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IDE","DRTSW","BK4097","BK4124","DRTS","BK4082","OS","CPS"],"gpt_icon":0},{"id":"2506749298","title":"Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2506749298","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506749298?lang=en_us&edition=fundamental","pubTime":"2025-01-25 23:05","pubTimestamp":1737817500,"startTime":"0","endTime":"0","summary":"Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone. AUSTIN, Texas,, January 25, 2025----Natera, Inc. , a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB  / SWOG 80702 study. The study will be presented today, Jan. 25, 2025 as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium  in San Francisco, CA.Signatera-positivity after surgery was predictive of a disease-free survival  and overall survival  benefit with the addition of celecoxib to adjuvant FOLFOX. The addition of celecoxib to SOC chemotherapy significantly improved DFS compared to placebo  among Signatera-positive patients with a three-year DFS of 44.1% versus 26.6%. Similar results were seen for OS . No survival benefit was seen by adding celecoxib to chem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-announces-successful-readout-randomized-150500221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","CLIA","LU0053671581.USD","LU2065171311.SGD","CRC","BK4585","LU2360107671.USD","BK4166","LU2065170008.USD","LU2065169927.USD","BK4134","BK4139","BK4213","DFS","LU1791807156.HKD","LU2065171402.SGD","LU0012050646.USD","LU1861220207.SGD","BK4097","LU1861217088.USD","LU0106831901.USD","LU1668664300.SGD","LU2065731478.USD","LU0106261612.USD","LU0456854461.SGD","LU2264538146.SGD","LU0266512127.USD","III","OS","LU1064131342.USD","LU1988902786.USD","NTRA","SOC"],"gpt_icon":0},{"id":"2505712611","title":"Thousands of Hyundai iLoad, iMax people movers recalled over fears manufacturing fault could spark fire","url":"https://stock-news.laohu8.com/highlight/detail?id=2505712611","media":"Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505712611?lang=en_us&edition=fundamental","pubTime":"2025-01-22 18:29","pubTimestamp":1737541773,"startTime":"0","endTime":"0","summary":"Thousands of cars made by a popular manufacturer have been recalled over a major defect – just days after a similar warning affecting thousands of other vehicles was sent out.","market":"us","thumbnail":"https://images.perthnow.com.au/publication/C-17472090/1ba966bab399b798e7e2c53d987b653fd2c000c0-16x9-x0y177w1885h1060.jpg","type":0,"news_type":0,"thumbnails":["https://images.perthnow.com.au/publication/C-17472090/1ba966bab399b798e7e2c53d987b653fd2c000c0-16x9-x0y177w1885h1060.jpg"],"rights":{"source":"perthnow_stock","url":"https://www.perthnow.com.au/news/thousands-of-hyundai-iload-imax-people-movers-recalled-over-fears-manufacturing-fault-could-spark-fire-c-17472090","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.perthnow.com.au/news/thousands-of-hyundai-iload-imax-people-movers-recalled-over-fears-manufacturing-fault-could-spark-fire-c-17472090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"perthnow_stock","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2505026940","title":"Hyundai recalls 4700 cars over potentially dangerous fuel defect","url":"https://stock-news.laohu8.com/highlight/detail?id=2505026940","media":"Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505026940?lang=en_us&edition=fundamental","pubTime":"2025-01-21 09:47","pubTimestamp":1737424057,"startTime":"0","endTime":"0","summary":"One of Australia’s most-purchased car makers has been forced to recall more than 4700 cars over a potentially dangerous issue.","market":"us","thumbnail":"https://images.perthnow.com.au/publication/C-17455815/342c2540407d2003622d6bddfd9da3469f9d49c1-16x9-x0y0w2048h1152.jpg","type":0,"news_type":0,"thumbnails":["https://images.perthnow.com.au/publication/C-17455815/342c2540407d2003622d6bddfd9da3469f9d49c1-16x9-x0y0w2048h1152.jpg"],"rights":{"source":"perthnow_stock","url":"https://www.perthnow.com.au/news/hyundai-recalls-4700-cars-over-potentially-dangerous-fuel-defect-c-17455815","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.perthnow.com.au/news/hyundai-recalls-4700-cars-over-potentially-dangerous-fuel-defect-c-17455815","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"perthnow_stock","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2504164913","title":"FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER","url":"https://stock-news.laohu8.com/highlight/detail?id=2504164913","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504164913?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:01","pubTimestamp":1737122460,"startTime":"0","endTime":"0","summary":"Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC. \"Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and fewer than one in five people diagnosed with metastatic disease survive beyond five years after diagnosis,\" said Jay Bradner, M.D., executive vice president of Research and Development at Amgen.2 \"LUMAKRAS plus Vectibix offers a targeted, biomarker-driven combination therapy that helps delay disease progression more effectively than the investigated standard of care. This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer.\". TheKRASG12C mutation is present in approximately 3-5% of colorec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fda-approves-lumakras-sotorasib-combination-140100845.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-lumakras-sotorasib-combination-140100845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","AST","LU0266512127.USD","BK4139","OS","ALT","BK4195","LU0456854461.SGD","IE0002141913.USD","FOR","BK4211","LU1057294990.SGD","BK4599","BK4566","LU0889565916.HKD","BK4213","BK4581","BK4024","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4203","BK4534","HR","LU0868494617.USD","SOC","LU1571399168.USD","BK4533","PMR","IE00BJT1NW94.SGD","LU0289739699.SGD","BK4225","ORR","IE00BFTCPJ56.SGD","BK4585","PFS","SG9999001440.SGD","LU1878469433.USD","IE0009355771.USD","LU2242652126.USD","LU1983299246.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","CRC","LU0109394709.USD","BK4588","LU0320765992.SGD","LU1061106388.HKD","AMGN"],"gpt_icon":0},{"id":"2504994978","title":"OneStream Is Maintained at Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2504994978","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504994978?lang=en_us&edition=fundamental","pubTime":"2025-01-17 03:09","pubTimestamp":1737054540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2025 14:09 ET (19:09 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2503209990","title":"RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503209990","media":"CNW Group","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503209990?lang=en_us&edition=fundamental","pubTime":"2025-01-16 22:11","pubTimestamp":1737036660,"startTime":"0","endTime":"0","summary":"Phase 3 MARIPOSA-2 study showed RYBREVANT in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.1. TORONTO, Jan. 16, 2025 /CNW/ - Johnson & Johnson  announced today that Health Canada has issued a Notice of Compliance  for RYBREVANT  in combination with carboplatin and pemetrexed  for the treatment of patients with locally advanced or metastatic non-small cell lung cancer  with activating epidermal growth factor receptor  Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.1. \"A lung cancer diagnosis can be devastating. Thisapproval of RYBREVANTis welcome news for patients, offering hope against this difficult-to-treat disease and a chance to spend more quality time with their loved ones,\"says Shem Singh***, Executive Director, Lung Cancer Canada. \"Having this new therapeutic option underscores the importance of ongoing resear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rybrevant-plus-chemotherapy-approved-canada-141100584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4588","PFS","LU1066053197.SGD","IE00BVYPNW00.USD","LU1066051498.USD","LU1718418525.SGD","LU1894683264.USD","LU1988902786.USD","LU0203345920.USD","LU0912757837.SGD","LU1057294990.SGD","IE0009355771.USD","IE00B1BXHZ80.USD","JNJ","LU1674673691.USD","BK4603","LU0345769631.USD","IE00BGHQF631.EUR","LU1221951046.USD","NOC","IE00B2B36J28.USD","BK4097","BK4585","LU0234572021.USD","BK4533","BK4187","LU1280957306.USD","LU1674673428.USD","LU1929549753.HKD","IE00B42XCP33.USD","LU1066051811.HKD","LU0345769128.USD","LU1032955483.USD","BK4592","LU1261432733.SGD","LU1506573853.SGD","BK4195","IE00BSNM7G36.USD","OS","BK4007","IE00BVYPNV92.GBP","LU0234570918.USD","LU2112291526.USD","IE0034235303.USD","LU1894683348.USD","LU1066051225.USD","IE00BJT1NW94.SGD","IE00BDGV0183.EUR","ORR"],"gpt_icon":0},{"id":"2503998206","title":"OneStream Raised to Overweight From Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2503998206","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503998206?lang=en_us&edition=fundamental","pubTime":"2025-01-16 20:00","pubTimestamp":1737028800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2025 07:00 ET (12:00 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2503962732","title":"Morgan Stanley Upgrades Onestream to Overweight From Equalweight, Keeps $37 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2503962732","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503962732?lang=en_us&edition=fundamental","pubTime":"2025-01-16 19:22","pubTimestamp":1737026544,"startTime":"0","endTime":"0","summary":"Onestream (OS) has an average rating of buy and mean price target of $36.18, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OS"],"gpt_icon":0},{"id":"2503644966","title":"Onestream, Inc. Class A Upgraded to Overweight on Strong Growth Prospects and Attractive Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2503644966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503644966?lang=en_us&edition=fundamental","pubTime":"2025-01-16 18:15","pubTimestamp":1737022527,"startTime":"0","endTime":"0","summary":"Onestream, Inc. Class A (OS – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/onestream-inc-class-a-upgraded-to-overweight-on-strong-growth-prospects-and-attractive-valuation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/onestream-inc-class-a-upgraded-to-overweight-on-strong-growth-prospects-and-attractive-valuation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS"],"gpt_icon":0},{"id":"2503890646","title":"New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503890646","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503890646?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:00","pubTimestamp":1736946000,"startTime":"0","endTime":"0","summary":"Application accepted for U.S. FDA Real-Time Oncology Review  based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1. RARITAN, N.J., Jan. 15, 2025 /PRNewswire/ -- Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration  for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin -unresponsive high-risk non-muscle-invasive bladder cancer  with carcinoma in situ , with or without papillary tumors. This submission is being reviewed by the FDA through the Real-Time Oncology Review  program, which allows the FDA to review data before the complete application is formally submitted and helps ensure treatments are available for patients as soon as possible.TAR-200 is an investigational intravesical drug releasing system designed to provide sustained local deliveryof gemcitabine into the bladder. It is placed into the bladder by a healthcare professional ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/drug-application-initiated-u-fda-130000101.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/drug-application-initiated-u-fda-130000101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BK4588","LU0345770308.USD","IE00BVYPNW00.USD","BK4581","LU0912757837.SGD","LU1057294990.SGD","LU1430594728.SGD","IE00B1BXHZ80.USD","JNJ","IE0002270589.USD","LU0889566641.SGD","IE00BGHQF631.EUR","LU0640476718.USD","LU0882574055.USD","BK4161","CR","LU1732800096.USD","LU1585245621.USD","LU0098860793.USD","LU2133065610.SGD","BK4097","BK4533","BK4504","LU1674673428.USD","IE00B42XCP33.USD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","LU2347655156.SGD","SG9999001440.SGD","LU0345769128.USD","LU1732799900.SGD","IE00B4R5TH58.HKD","LU1261432733.SGD","LU0058720904.USD","LU1506573853.SGD","OS","IE000M9KFDE8.USD","LU1244550221.USD","BCG","BK4007","IE00B3PB1722.GBP","LU0234570918.USD","IE0034235303.USD","LU0320765646.SGD","LU1032466523.USD","LU1935042991.SGD","LU1894683348.USD","SG9999002232.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2503309960","title":"Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309960","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309960?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769600,"startTime":"0","endTime":"0","summary":"Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials. Approval would mark the first for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in lung cancer. WILMINGTON, Del., January 13, 2025----AstraZeneca and Daiichi Sankyo’s Biologics License Application  for datopotamab deruxtecan  has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  who have received prior systemic therapies, including an EGFR-directed therapy.Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, said: \"Treating advanced EGFR-mutated non-small cell lung cancer presents a significant challenge due to the limited efficacy of available treatments once the disease has progressed following front-line therapies, including the use of an EGFR-tyrosine kinase inhibitor. If approved, datopotamab deruxtecan could become ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-granted-priority-review-120000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","LU0109394709.USD","BK4231","BK4585","LU2236285917.USD","ADC","BK4588","BK4568","LU2417539215.USD","LU0320765992.SGD","BK4080","BK4195","LU2462157665.USD","BK4007","PFS","BK4097","LU0889565916.HKD","LU2456880835.USD","OS","AZN","LU1829250122.USD"],"gpt_icon":0},{"id":"2503326508","title":"Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503326508","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503326508?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:00","pubTimestamp":1736751600,"startTime":"0","endTime":"0","summary":"Application based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 and TROPION-PanTumor01 phase 1 trials. TOKYO & BASKING RIDGE, N.J., January 13, 2025----Daiichi Sankyo  and AstraZeneca’s  Biologics License Application  for datopotamab deruxtecan  has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  who have received prior systemic therapies, including an EGFR-directed therapy.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.\"Acquired resistance to front-line therapies and, ultimately, disease progression are unfortunate realities for most patients with advanced EGFR-mutated non-small cell lung cancer,\" said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-granted-priority-review-070000802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4080","BK4097","DSKYF","IE00B66KJ199.SGD","BK4231","BK4157","DSNKY","PFS","OS","BK4195","IE0031619046.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4211","ADC","AEIS","PBD"],"gpt_icon":0},{"id":"2503949583","title":"Press Release: Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503949583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503949583?lang=en_us&edition=fundamental","pubTime":"2025-01-13 05:00","pubTimestamp":1736715600,"startTime":"0","endTime":"0","summary":"Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025. -- Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 --. -- Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion --. -- Presentation and webcast at 43 Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13 at 5:15 p.m. PT / 8:15 p.m. ET --. Preliminary Fiscal Year 2024 Financial Results & 2025 Financial Guidance. Exelixis is providing the following preliminary unaudited 2024 financial results and financial guidance for 2025. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of CABOMETYX  for the treatment of patients with previously treated advanced neuroendocrine tumors . The U.S. Food and Drug Administration  is currentl","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456854461.SGD","BK4139","BK4585","EXEL","CRC","BK4554","BK4213","BK4211","BK4548","BK4588","BK4116","BK4232","BK4532","BK4022","BK4097","LU2286300806.USD","BK4202","NCI","NET","OS","PFS","R","LU0266512127.USD","BK4560","BK4195"],"gpt_icon":0},{"id":"2502614022","title":"Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2502614022","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502614022?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:00","pubTimestamp":1736456400,"startTime":"0","endTime":"0","summary":"Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007342/0/en/Mural-Oncology-Highlights-Pipeline-Progress-and-Anticipated-2025-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROC","OS","CTA","MURA","PRGS","BK4139","BK4097","LU2065732104.USD","BK4007"],"gpt_icon":0},{"id":"2502868290","title":"OneStream Announces Timing of its Fourth Quarter and Full-Year 2024 Financial Results Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2502868290","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502868290?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:30","pubTimestamp":1736371800,"startTime":"0","endTime":"0","summary":"BIRMINGHAM,Mich., Jan. 8, 2025 /PRNewswire/ -- OneStream, Inc. , the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions -- including financial close, consolidation, reporting, planning and forecasting, will report financial results for its fourth quarter ended December 31, 2024 and full-year 2024, after the market close on Tuesday, February 11, 2025. OneStream will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss its financial results.About OneStreamOneStream is how today's Finance teams can go beyond just reporting on the past and Take Finance Further by steering the business to the future. It's the leading enterprise finance platform that unifies financial and operational data, embeds AI for better decisions and productivity, and empowers the CFO to become a critical driver of business strategy and execution.We deliver a comprehensive cloud-based platform to moder","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-announces-timing-fourth-quarter-213000920.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-announces-timing-fourth-quarter-213000920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2501742284","title":"China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501742284","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501742284?lang=en_us&edition=fundamental","pubTime":"2025-01-08 17:55","pubTimestamp":1736330100,"startTime":"0","endTime":"0","summary":"- First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care for nearly 40 years1. - NMPA approval based on the global Phase 3 EV-302 trial  where the treatment combination significantly improved overall survival and progression-free survival outcomes1. TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced that China's National Medical Products Administration  has approved PADCEV in combination with KEYTRUDA  for adult patients with locally advanced or metastatic urothelial cancer . The treatment combination willprovide a new therapeutic option to patients with la/mUC in Chinaand offer an alternative to platinum-containing chemotherapy, the standard of care for nearly 40 years.1. Professor Huang Jian, Lead Primary Investigator of the EV-302 Study in China, Chairman of the Urology Subcommittee of the Chinese Medical Association, Depart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0306806265.USD","LU1093756168.USD","ALPMY","LU1917777945.USD","LU2112291526.USD","IE0002141913.USD","ALPMF","SG9999015341.SGD","LU1941712348.USD","CSCO","MRK","LU0321505439.SGD","SG9999014567.USD","IE00B19Z3B42.SGD","BK4550","LU2237443382.USD","ADC","LU1989772923.USD","LU0950375773.USD","LU1894683264.USD","PFE","LU0203345920.USD","LU0965509010.AUD","PFS","OS","IE00BFMHRM44.USD","LU0965509101.SGD","AEIS","LU2506952097.USD","IE0009355771.USD","BK4599","BK4097","LU0942090050.USD","LU0985481810.HKD","LU1291159041.SGD","LU0320765489.SGD","SG9999003800.SGD","LU0265550359.USD","LU1037948897.HKD","BK4579","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","LU2361044865.SGD","LU1066051811.HKD","SG9999014542.SGD","LU0306807586.USD","IE00BSNM7G36.USD","SG9999001176.SGD","LU1244550577.SGD","NHLD","SG9999001440.SGD"],"gpt_icon":1},{"id":"2501785999","title":"The Automotive Playground at CES 2025: AI, EVs, Flying Cars & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2501785999","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501785999?lang=en_us&edition=fundamental","pubTime":"2025-01-07 22:12","pubTimestamp":1736259120,"startTime":"0","endTime":"0","summary":"The Consumer Electronics Show  has been long known as the premier tech event in the United States. Initially a haven for gadget enthusiasts, it has evolved into a massive stage for the automotive industry. From cutting-edge electric vehicles  to advanced artificial intelligence  integrations, CES now serves as a pivotal platform for automakers to debut innovations that blend technology and mobility. The 2025 edition, which kicks off today and will run till Jan. 10 in Las Vegas, is expected to continue this trend with a host of groundbreaking announcements and futuristic displays.Artificial intelligence and autonomous driving technology remain at the forefront of automotive innovation. Automakers, from established giants to emerging brands, have been rapidly advancing AI-driven features, driver assistance systems, and self-driving capabilities. Many are now poised to roll out these innovations, pending changes in legislation.Mercedes-Benz had already ramped up AI advancements with its C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/automotive-playground-ces-2025-ai-141200879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4099","BK4585","TM","HMC","BK4505","OS","BK4526","BK4555","BK4588","03160","BK4097","EVS.SI","XPEV","BAMXF","BK4551"],"gpt_icon":1},{"id":"2501082201","title":"RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2501082201","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501082201?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:00","pubTimestamp":1736254800,"startTime":"0","endTime":"0","summary":"Median overall survival improvement expected to exceed one year. First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer. \"These new findings reinforce the clinically meaningful impact this chemotherapy-free regimen can have for patients worldwide with non-small cell lung cancer and represent the first overall survival benefit over the current standard of care,\" said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. \"Withless than 20 percent of patients living beyond five years, an incredible unmet need remains for EGFR-positive lung cancer. These MARIPOSA results show RYBREVANT plus LAZCLUZE can extend survival beyond the c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-plus-lazcluze-130000654.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-plus-lazcluze-130000654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051811.HKD","LU0234570918.USD","BK4533","LU2089984988.USD","LU1244550577.SGD","LU0795875169.SGD","BK4592","LU0345769631.USD","LU0640476718.USD","LU1032955483.USD","IE00BFTCPJ56.SGD","LU1221951046.USD","BK4559","IE00BGHQF631.EUR","LU1894683348.USD","IE00BVYPNV92.GBP","OS","LU2602419157.SGD","PFS","LU1066051225.USD","SG9999002232.USD","LU0234572021.USD","JNJ","LU1066051498.USD","LU1935042991.SGD","LU2133065610.SGD","LU0795875086.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4097","IE0034235303.USD","LU0114720955.EUR","LU1506573853.SGD","LU0320765646.SGD","LU1280957306.USD","LU1221951129.SGD","LU0889566641.SGD","LU0345770993.USD","IE00BSNM7G36.USD","IE00B42XCP33.USD","LU0882574055.USD","LU1261432733.SGD","LU1196500208.SGD","LU1674673691.USD","IE0002141913.USD","LU1032466523.USD","LU1732799900.SGD","LU0345769128.USD","LU2468319806.SGD","IE00B19Z3B42.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3158,"buy":0.5789,"hold":0.1053,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5789,"analysts":19,"updateTime":1742356800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-04-29","current":-17.178873,"percent":0.901639,"low":-1655.61542,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"high":-14.493656,"avg":-426.817199,"sd":615.425447,"marketCap":3714089583},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-04-29","current":-17.178873,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"marketCap":3714089583}],"updateTime":1746085438295}}}